Novo Nordisk offers cheaper Wegovy

Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.

VK2735's manufacturing alliance with CordenPharma

Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735

BRP - a new GLP1-like peptide

We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.

HIMS ends compounded Semaglutide offering

Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.

Semaglutide removed from shortage list

It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.

Mexico and GLP1s

We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.

Shortages threaten corporate profits, likely to end soon

We think the GLP1 shortage is going to end in the first half of 2025. Here's why.

Ozempic approved for Chronic Kidney Disease

The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.

Tradjenta: An alternative to GLP1 for Type 2 Diabetes

We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.

GLP1 use by younger people

We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.

Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

The battle for compounded GLP1 continues

The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.